(Pyridin-4-yl)boronic acid → (R)-3'-[4-(4-Pyridyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one
Reaction equation
Br[C:2]1[CH:3]=[C:4]([N:7]2[CH2:11][C@:10]3([CH:16]4[CH2:17][CH2:18][N:13]([CH2:14][CH2:15]4)[CH2:12]3)[O:9][C:8]2=[O:19])[S:5][CH:6]=1.[N:20]1[CH:25]=[CH:24][C:23](B(O)O)=[CH:22][CH:21]=1>>[N:20]1[CH:25]=[CH:24][C:23]([C:2]2[CH:3]=[C:4]([N:7]3[CH2:11][C@:10]4([CH:16]5[CH2:17][CH2:18][N:13]([CH2:14][CH2:15]5)[CH2:12]4)[O:9][C:8]3=[O:19])[S:5][CH:6]=2)=[CH:22][CH:21]=1Participants
3
Procedure
The title compound was prepared by a method analogous to that described in Example 1 from (R)-3′-(4-bromothiophen-2-yl)spiro[1-azabicyclo[2.2.2]octan-3,5′-oxazolidin]-2′-one and pyridine-4-boronic acid. The solid obtained after flash chromatography was further purified by reverse phase HPLC on a Phenomenex® Polar RP column using a gradient of 5-45% acetonitrile/water (each solvent containing 0.1% trifluoroacetic acid as a buffer) as the eluant. The residue was partitioned between saturated aqueous potassium carbonate and chloroform and the chloroform layer was dried (magnesium sulfate), filtered and evaporated to give the title compound as a pale solid (74 mg), m/z 342 (MH+).
Workup
- customThe title compound was prepared by a method analogous to
- customThe solid obtained after flash chromatography
- customwas further purified by reverse phase HPLC on a Phenomenex® Polar RP column
- additioncontaining 0.1% trifluoroacetic acid as a buffer) as the eluant
- customThe residue was partitioned between saturated aqueous potassium carbonate and chloroform
- dry with materialthe chloroform layer was dried (magnesium sulfate)
- filtrationfiltered
- customevaporated
Sources & evidence
- ORD record
- ord-081010f5a3fd42cdaa737a16a32ac461
- Source dataset
- uspto-grants-2009_04
- Patent number
- US07514567B2
Reaction notes
Loading…